Crinetics Pharmaceuticals Stock Net Asset
| CRNX Stock | USD 50.13 0.75 1.52% |
Crinetics Pharmaceuticals fundamentals help investors to digest information that contributes to Crinetics Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Crinetics Stock. The fundamental analysis module provides a way to measure Crinetics Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Crinetics Pharmaceuticals stock.
Crinetics | Net Asset |
Crinetics Pharmaceuticals Company Net Asset Analysis
Crinetics Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Crinetics Pharmaceuticals Net Asset | 635.35 M |
Most of Crinetics Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Crinetics Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Crinetics Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Crinetics Pharmaceuticals is extremely important. It helps to project a fair market value of Crinetics Stock properly, considering its historical fundamentals such as Net Asset. Since Crinetics Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Crinetics Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Crinetics Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Crinetics Total Assets
Total Assets |
|
Based on the recorded statements, Crinetics Pharmaceuticals has a Net Asset of 635.35 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Crinetics Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Crinetics Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Crinetics Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Crinetics Pharmaceuticals by comparing valuation metrics of similar companies.Crinetics Pharmaceuticals is currently under evaluation in net asset category among related companies.
Crinetics Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Crinetics Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Crinetics Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Crinetics Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Crinetics Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Crinetics Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Crinetics Pharmaceuticals' value.| Shares | First Light Asset Management, Llc | 2023-03-31 | 2 M | Orbimed Advisors, Llc | 2023-12-31 | 1.7 M | Geode Capital Management, Llc | 2023-12-31 | 1.4 M | Goldman Sachs Group Inc | 2023-12-31 | 1.3 M | Perceptive Advisors Llc | 2023-12-31 | 1.3 M | Cormorant Asset Management, Llc | 2023-12-31 | 1.1 M | Novo A/s | 2023-12-31 | 1.1 M | Eventide Asset Management, Llc | 2023-12-31 | 1.1 M | Saturn V Capital Management Llc | 2023-12-31 | 787.1 K | Blackrock Inc | 2023-12-31 | 5.3 M | Driehaus Capital Management Llc | 2023-12-31 | 5 M |
Crinetics Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (55.47) % | ||||
| Current Valuation | 2.93 B | ||||
| Shares Outstanding | 78.86 M | ||||
| Shares Owned By Insiders | 2.10 % | ||||
| Shares Owned By Institutions | 97.74 % | ||||
| Number Of Shares Shorted | 4.91 M | ||||
| Price To Earning | (12.03) X | ||||
| Price To Book | 6.45 X | ||||
| Price To Sales | 865.90 X | ||||
| Revenue | 4.01 M | ||||
| Gross Profit | (125.49 M) | ||||
| EBITDA | (221.51 M) | ||||
| Net Income | (214.53 M) | ||||
| Cash And Equivalents | 408.51 M | ||||
| Cash Per Share | 7.60 X | ||||
| Total Debt | 51.73 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.94 X | ||||
| Book Value Per Share | 11.14 X | ||||
| Cash Flow From Operations | (166.31 M) | ||||
| Short Ratio | 4.77 X | ||||
| Earnings Per Share | (3.77) X | ||||
| Target Price | 61.69 | ||||
| Number Of Employees | 290 | ||||
| Beta | 0.64 | ||||
| Market Capitalization | 3.79 B | ||||
| Total Asset | 635.35 M | ||||
| Retained Earnings | (653.7 M) | ||||
| Working Capital | 530.21 M | ||||
| Current Asset | 44.96 M | ||||
| Current Liabilities | 2.41 M | ||||
| Net Asset | 635.35 M |
About Crinetics Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Crinetics Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crinetics Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crinetics Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Crinetics Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crinetics Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crinetics Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Crinetics Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crinetics Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crinetics Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crinetics Pharmaceuticals to buy it.
The correlation of Crinetics Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crinetics Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crinetics Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crinetics Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Crinetics Pharmaceuticals Piotroski F Score and Crinetics Pharmaceuticals Altman Z Score analysis. For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for Crinetics Stock analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |
Is Crinetics Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crinetics Pharmaceuticals. If investors know Crinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crinetics Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.77) | Revenue Per Share 0.069 | Quarterly Revenue Growth (1.00) | Return On Assets (0.28) | Return On Equity (0.50) |
The market value of Crinetics Pharmaceuticals is measured differently than its book value, which is the value of Crinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Crinetics Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Crinetics Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crinetics Pharmaceuticals' market value can be influenced by many factors that don't directly affect Crinetics Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crinetics Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crinetics Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crinetics Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.